Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 10Carcinoma, Renal Cell 4Neoplasm Metastasis 3Seminoma 2Primary Myelofibrosis 2Multiple Myeloma 2Kidney Neoplasms 2Urogenital Neoplasms 1Thymoma 1Thrombocytosis 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma, Endometrial Stromal 1Rhabdomyosarcoma, Embryonal 1Prostatic Diseases 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Mesothelioma 1Melanoma 1Mastocytosis 1Malignant mesenchymal tumor 1Lymphoma, Non-Hodgkin 1

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Abdominal Neoplasms × Imatinib Mesylate × Genitourinary × Clear all
NCT01316458 2017-06-01

Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy

Novartis

Phase 2 Completed
51 enrolled
Genitourinary

Abdominal Neoplasms, Genital Diseases, Male, Genital Neoplasms, Male, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡